A double-blind, double-dummy, randomized, placebo-controlled trial to evaluate the effect of statin therapy on triglyceride levels in Mexican hypertriglyceridemic patients

References

• Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000;86:943-9
   PubMed Web of Science ®Google Scholar
• Sone H, Tanaka S, Tanaka S, et al. Serum level of triglycerides is a potential risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab 2011;96:3448-56
   PubMed Web of Science ®Google Scholar
• Miller M, Cosgrove B, Havas S. Update on the role of triglycerides as a risk factor for coronary heart disease. Curr Atheroscler Rep 2002;4:414-18
   PubMedGoogle Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 2001;285:2486-97
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and Management of the Metabolic Syndrome. An American Heart Association/National Heart, Lung, and Blood Institute. Scientific Statement. Circulation 2005;112:2735-52
   PubMed Web of Science ®Google Scholar
• Paoletti R, Bolego C, Poli A, et al. Metabolic syndrome, inflammation and atherosclerosis. Vascular Health Risk Management. 2006:2:145-52
   PubMedGoogle Scholar
• Roseman HM, Blonde L, Brixner DI, et al. Progression from obesity to type 2 diabetes: lipotoxicity, glucotoxicity, and implications for management. J Manag Care Pharm. 2005;11:s3-11
   Google Scholar
• Principales causas de mortalidad general, 2010. SSA; Mex; 2010. http://sinais.salud.gob.mx/mortalidad/ consulted last time on December 19th 2012
   Google Scholar
• Rull JA, Aguilar-Salinas CA, Rojas R, et al. Epidemiology of type 2 diabetes in Mexico. Arch Med Res 2005;36:188-96
   PubMed Web of Science ®Google Scholar
• Isordia-Salas I, Santiago-Germán D, Rodríguez-Navarro H, et al. Prevalence of metabolic syndrome components in an urban Mexican simple: comparison between two classifications. Diabetes Res 2012:202-540
   Google Scholar
• Escobedo-de la Peña J, Buitrón-Granados LV, Ramírez-Martínez JC, et al. Diabetes in México. CARMELA Study. Cir Cir 2011;79:424-31
   PubMedGoogle Scholar
• Aguilar-Salinas C, Gomez Perez FJ, Rull J, et al. Prevalence of dyslipidemias in the Mexican national health and nutrition survey 2006. Salud Publica Mex 2010; 52:s44-53
   Google Scholar
• The FIELD Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005;26:849-61
   Google Scholar
• Tonkin A, Hunt D, Voysey M, et al. Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate intervention and Event Lowering in Diabetes (FIELD) study. Am Heart J 2012;163:508-14
   PubMed Web of Science ®Google Scholar
• Hermans MP. Impact of fenofibrate on type 2 diabetes patients with features of the metabolic syndrome: subgroup analysis of FIELD. Curr Cardiol Rev 2010;6:112-18
   PubMedGoogle Scholar
• Davidson MH, Bays HE, Stein E, et al. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects Clin Cardiol 2006;29:268-73
   PubMed Web of Science ®Google Scholar
• Wolffenbuttel BHR, Franken AAM, Vincent HH. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes – CORALL study. J Intern Med 2005;257:531-9
   PubMed Web of Science ®Google Scholar
• Wlodarczyk J, Sullivan D, Smith M. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. Am J Cardiol 2008;102:1654-62
   PubMed Web of Science ®Google Scholar
• Gray J, Edwards SJ, Lip GY. Comparison of sequential rosuvastatin doses in hypercholesterolemia: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2010;26:537-47
   PubMed Web of Science ®Google Scholar
• Jones, PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). Am J Cardiol 2003;92:152-60
   PubMed Web of Science ®Google Scholar
• Harley CR, Gandhi SK, Heien H, et al. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care. Expert Opin Pharmacother 2008;9:669-76
   PubMed Web of Science ®Google Scholar
• Stalenhoef1 AFH, Ballantyne CM, Sarti C, et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J 2005;26:2664-72
   PubMed Web of Science ®Google Scholar
• Hunninghak DB, Stein EA, Bays HE, et al. Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia. Coron Artery Dis 2004;15:115-23
   PubMed Web of Science ®Google Scholar
• Roth EM, McKenney JM, Kelly MT, et al. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. Am J Cardiovasc Drugs 2010;10:175-86
   PubMed Web of Science ®Google Scholar
• Weng TC, Yang YH, Lin SJ, et al. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010;35:139-51
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Mohanavelu S, Raichlen JS, et al. Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study). Am J Cardiol 2009;104:29-35
   PubMed Web of Science ®Google Scholar
• Zhu JR, Tomlinson B, Ro YM, et al. Randomized study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study). Curr Med Res Opin 2007;23:3055-68
   PubMed Web of Science ®Google Scholar
• Saito Y, Yamada N, Shirai K, et al. Effect of rosuvastatin 5–20 mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia. Atherosclerosis 2007;194:505-11
   PubMed Web of Science ®Google Scholar
• Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk. A systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113-32
   PubMed Web of Science ®Google Scholar
• Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998;97:1029-36
   PubMed Web of Science ®Google Scholar
• Suadicani P, Hein HO, Gyntelberg F. Antihypertensive treatment, high triglycerides, and low high-density lipoprotein cholesterol and risk of ischemic heart disease mortality: a 16-year follow-up in the Copenhagen male study. Metab Syndr Relat Disord 2010;8:215-22
   PubMed Web of Science ®Google Scholar
• Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-19
   PubMedGoogle Scholar
• Bos G, Dekker JM, Nijpels G, et al. Hoorn Study. A combination of high concentrations of serum triglyceride and non-high-density-lipoprotein-cholesterol is a risk factor for cardiovascular disease in subjects with abnormal glucose metabolism – The Hoorn Study. Diabetologia 2003;46:910-16
   PubMed Web of Science ®Google Scholar
• Tanne D, Koren-Morag N, Graff E, et al, for the BIP Study Group. Blood lipids and first-ever ischemic stroke/transient ischemic attack in the bezafibrate infarction prevention (BIP) registry. High triglycerides constitute an independent risk factor. Circulation 2001;104:2892--7
   PubMed Web of Science ®Google Scholar
• McCullough PA, Ahmed AB, Zughaib MT, et al. Treatment of hypertriglyceridemia with fibric acid derivatives: impact on lipid subfractions and translation into a reduction in cardiovascular events. Rev Cardiovasc Med 2011;12:173-85
   PubMed Web of Science ®Google Scholar
• Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation 2007;115:450-8
   PubMed Web of Science ®Google Scholar
• The ACCORD study group. Effect of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74
   PubMed Web of Science ®Google Scholar
• Mora S, Glynn RJ, Boekholdt M, et al. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy. JUPITER (Justification for the Use of Statins in Prevention: An Interventional Trial Evaluating Rosuvastatin. J Am Coll Cardiol 2012;59:1521-8
   PubMed Web of Science ®Google Scholar